Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $5.7 million.

  • Catalyst Pharmaceuticals' Share-based Compensation rose 2816.46% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 1386.78%. This contributed to the annual value of $22.3 million for FY2024, which is 5614.74% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Share-based Compensation of $5.7 million as of Q3 2025, which was up 2816.46% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Share-based Compensation ranged from a high of $8.2 million in Q1 2024 and a low of $1.5 million during Q4 2021
  • Over the past 5 years, Catalyst Pharmaceuticals' median Share-based Compensation value was $3.3 million (recorded in 2023), while the average stood at $3.7 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Share-based Compensation soared by 18520.06% in 2024, and later tumbled by 2907.37% in 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Share-based Compensation (Quarter) stood at $1.5 million in 2021, then surged by 30.84% to $1.9 million in 2022, then skyrocketed by 120.66% to $4.2 million in 2023, then rose by 21.67% to $5.2 million in 2024, then grew by 9.65% to $5.7 million in 2025.
  • Its Share-based Compensation was $5.7 million in Q3 2025, compared to $7.6 million in Q2 2025 and $5.8 million in Q1 2025.